Extended Data Fig. 1: PRMT9 levels are elevated in AML.
a–h, PRMTs mRNA levels in cancers from TCGA PanCancer Atlas. AML (n = 173), Lung adenocarcinoma (LUAD, n = 510), Lung squamous cell carcinoma (LUSC, n = 484), Colon Adenocarcinoma (COAD, n = 438), Pancreatic adenocarcinoma (PAAD, n = 177), Breast Cancer (BRCA, n = 1082), Prostate adenocarcinoma (PRAD, n = 493), Liver Hepatocellular Carcinoma (LIHC, n = 366), Glioblastoma (GBM, n = 160), Bladder Carcinoma (BLCA, n = 407). PRMT expression in AML (red) was compared with other cancers (only with significant difference were indicated). The violin plot in gray indicates PRMTs (except PRMT8 which is undetectable) level was significantly higher in AML than indicated cancer type. P values (a-h) were determined by unpaired two-sided t-tests. ‘n’ represents the number of patients. i–n, PRMTs protein levels in AML lines relative to those seen in lines representing the other deadly cancers. AML (n = 14), Lung Cancer (LC, n = 77), COAD (n = 29), PAAD (n = 17), BRCA (n = 29), PRAD (n = 5), LIHC (n = 12), GBM (n = 11), BLCA (n = 9) and Acute Lymphoblastic Leukemia (ALL, n = 8). Data was based on DepMap. P values were determined by unpaired two-sided t test. ‘n’ represents number of cancer cell lines. o, PRMT9 levels in AML (n = 10) and B-NHL (n = 8) lines relative to lines from other deadly cancers (n = 330), based on DepMap. P values were determined by one-way ANOVA. ‘n’ represents number of cell lines. p, PRMT9 protein levels in lines from most-deadly cancers, (n = 1). q, Expression level of LSC-signature-genes in LSC (n = 383 cells) and Blast (n = 1191 cells) based on MA9 scRNAseq analyses. P value was determined by unpaired two-sided t test. r, Q-PCR analysis of PRMT9 levels in AML CD34+ cells from an in-house cohort (n = 94 patients) and from PBSCs from healthy donors (n = 19). PRMT9 levels were normalized to β-actin. P value was determined by unpaired two-sided t test.
